Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DSSZL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
36924655 ADC 13
|
|||||
| Synonyms |
ADC 13
Click to Show/Hide
|
|||||
| Organization |
Seoul National University.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site-specific conjugation via re-bridging.
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 6.9 uM | Moderate CD276 expression (CD276 ++) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-468 cell.
|
||||
| In Vitro Model | Mammary carcinoma | 4T1 cells | CVCL_0125 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 7.7 uM | Moderate CD276 expression (CD276 ++) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-231 cell.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 13.1 uM | High CD276expression (CD276 +++) | ||
| Method Description |
The in vitro antitumor efficacy of ADC was assessed using the 4T1 cell.
|
||||
| In Vitro Model | Mammary carcinoma | 4T1 cells | CVCL_0125 | ||
References